Activation of the sigma-1 receptor or SIGMAR1 — whose production is typically increased with age, but reduced in people with Alzheimer’s disease — drives a series of neuroprotective effects, including the clearance of unnecessary or damaged cellular components, a review study highlights. This supports the therapeutic potential of Anavex 2-73 (blarcamesine), and Anavex 3-71 (AF710B), in slowing the progression of Alzheimer’s, the researchers noted. The two orally administered SIGMAR1 activators, developed by Anavex Life Sciences,…
You must be logged in to read/download the full post.
The post Mechanisms Behind Anavex 2-73’s Benefits Highlighted in Review appeared first on BioNewsFeeds.